Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapy.
SBRT
Stereotactic Body Radiation Therapy
circulating tumor cells
liquid biopsy
oligometastatic prostate cancer
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
06 Sep 2024
06 Sep 2024
Historique:
revised:
31
07
2024
received:
12
06
2024
accepted:
23
08
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
aheadofprint
Résumé
Stereotactic body radiation therapy (SBRT) is an effective metastasis-directed therapy for managing oligometastatic prostate cancer patients. However, it lacks reliable biomarkers for risk stratification. Circulating Tumor Cells (CTC) show promise as minimally invasive prognostic indicators. This study evaluates the prognostic value of CTC in oligorecurrent hormone-sensitive prostate cancer (orHSPC). orHSPC patients with 1-3 nodal and/or bone metastases undergoing SBRT were enrolled (N = 35), with a median follow-up time of 42.1 months. CTC levels were measured at baseline (T0), 1 month (T1), and 3 months (T2) post-SBRT using a novel metabolism-based assay. These levels were correlated with clinical outcomes through Cox-regression and Kaplan-Meier analyses. Median CTC counts were 5 at T0, 8 at T1, and 5 at T2 with no significant variation over time. Multivariate analysis identified high (≥5/7.5 mL) T0 CTC counts (HR 2.9, 95% CI 1.3-6.5, p = 0.01, median DPFS 29.7 vs. 14.0 months) and having more than one metastasis (HR 3.9, 95% CI 1.8-8.6, p < 0.005, median DPFS 34.1 vs. 10.7 months) as independent predictors of distant progression-free survival (DPFS). CTC assessment successfully stratified patients with a single metastasis (HR 3.4, 95% CI 1.1-10.2, p = 0.03, median DPFS 42.1 vs. 16.7 months), but not those with more than one metastasis. Additionally, a combined score based on CTC levels and the number of metastases effectively stratified patients. The study demonstrates that hypermetabolic CTC could enhance risk stratification in orHSPC patients undergoing SBRT, particularly in patients with limited metastatic burden, potentially identifying patients with indolent disease who are suitable for tailored SBRT interventions.
Sections du résumé
BACKGROUND
BACKGROUND
Stereotactic body radiation therapy (SBRT) is an effective metastasis-directed therapy for managing oligometastatic prostate cancer patients. However, it lacks reliable biomarkers for risk stratification. Circulating Tumor Cells (CTC) show promise as minimally invasive prognostic indicators. This study evaluates the prognostic value of CTC in oligorecurrent hormone-sensitive prostate cancer (orHSPC).
METHODS
METHODS
orHSPC patients with 1-3 nodal and/or bone metastases undergoing SBRT were enrolled (N = 35), with a median follow-up time of 42.1 months. CTC levels were measured at baseline (T0), 1 month (T1), and 3 months (T2) post-SBRT using a novel metabolism-based assay. These levels were correlated with clinical outcomes through Cox-regression and Kaplan-Meier analyses.
RESULTS
RESULTS
Median CTC counts were 5 at T0, 8 at T1, and 5 at T2 with no significant variation over time. Multivariate analysis identified high (≥5/7.5 mL) T0 CTC counts (HR 2.9, 95% CI 1.3-6.5, p = 0.01, median DPFS 29.7 vs. 14.0 months) and having more than one metastasis (HR 3.9, 95% CI 1.8-8.6, p < 0.005, median DPFS 34.1 vs. 10.7 months) as independent predictors of distant progression-free survival (DPFS). CTC assessment successfully stratified patients with a single metastasis (HR 3.4, 95% CI 1.1-10.2, p = 0.03, median DPFS 42.1 vs. 16.7 months), but not those with more than one metastasis. Additionally, a combined score based on CTC levels and the number of metastases effectively stratified patients.
CONCLUSION
CONCLUSIONS
The study demonstrates that hypermetabolic CTC could enhance risk stratification in orHSPC patients undergoing SBRT, particularly in patients with limited metastatic burden, potentially identifying patients with indolent disease who are suitable for tailored SBRT interventions.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
Informations de copyright
© 2024 The Author(s). The Prostate published by Wiley Periodicals LLC.
Références
Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: reality or figment of imagination? Cancer. 2019;125:340‐352.
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8‐10.
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378‐382.
Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14:15‐25.
Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14:e28‐e37.
Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2012;2:215.
Berkovic P, De Meerleer G, Delrue L, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11:27‐32.
Decaestecker K, De Meerleer G, Lambert B, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014;9:135.
Triggiani L, Alongi F, Buglione M, et al. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer. 2017;116:1520‐1525.
Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis‐directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446‐453.
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR‐COMET): a randomised, phase 2, open‐label trial. The Lancet. 2019;393:2051‐2058.
Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650‐659.
Franceschini D, Cozzi L, Vernier V, et al. The pattern of failure after stereotactic radiation therapy (SRT) for oligo‐metastases: predictive factors for poly‐progression. J Cancer Res Clin Oncol. 2023;149(8):5173‐5179.
Mercier C, Claessens M, De Troyer B, et al. Survival outcomes and pattern of relapse after SABR for oligometastatic prostate cancer. Front Oncol. 2022;12:863609.
Zilli T, Achard V, Dal Pra A, et al. Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO‐ACROP Delphi consensus. Radiother Oncol. 2022;176:199‐207.
Stelcer E, Konkol M, Głȩboka A, Suchorska WM. Liquid biopsy in oligometastatic prostate Cancer‐A biologist's point of view. Front Oncol. 2019;9:775.
Aceto N, Toner M, Maheswaran S, Haber DA. En route to metastasis: circulating tumor cell clusters and epithelial‐to‐mesenchymal transition. Trends Cancer. 2015;1:44‐52.
Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration‐resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10:233‐239.
Scher HI, Heller G, Molina A, et al. Circulating tumor cell biomarker panel as an individual‐level surrogate for survival in metastatic castration‐resistant prostate cancer. J Clin Oncol. 2015;33:1348‐1355.
Pantel K, Hille C, Scher HI. Circulating tumor cells in prostate cancer: from discovery to clinical utility. Clin Chem. 2019;65:87‐99.
Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LWMM. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005;65:713‐718.
de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration‐resistant prostate cancer. Clin Cancer Res. 2008;14:6302‐6309.
Heller G, McCormack R, Kheoh T, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration‐resistant prostate cancer: a comparison with prostate‐specific antigen across five randomized phase III clinical trials. J Clin Oncol. 2018;36:572‐580.
Olmos D, Arkenau H‐T, Ang JE, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration‐resistant prostate cancer (CRPC): a single‐centre experience. Ann Oncol. 2009;20:27‐33.
Danila DC, Anand A, Schultz N, et al. Analytic and clinical validation of a prostate cancer‐enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur Urol. 2014;65:1191‐1197.
Vogelzang NJ, Fizazi K, Burke JM, et al. Circulating tumor cells in a phase 3 study of docetaxel and prednisone with or without lenalidomide in metastatic castration‐resistant prostate cancer. Eur Urol. 2017;71:168‐171.
Roviello G, Corona SP, Bonetta A, Cappelletti MR, Generali D. Circulating tumor cells correlate with patterns of recurrence in patients with hormone‐sensitive prostate cancer. Onco Targets Ther. 2017;10:3811‐3815.
Resel Folkersma L, San José Manso L, Galante Romo I, Moreno Sierra J, Olivier Gómez C. Prognostic significance of circulating tumor cell count in patients with metastatic hormone‐sensitive prostate cancer. Urology. 2012;80:1328‐1332.
Kuske A, Gorges TM, Tennstedt P, et al. Improved detection of circulating tumor cells in non‐metastatic high‐risk prostate cancer patients. Sci Rep. 2016;6:39736.
Thalgott M, Rack B, Maurer T, et al. Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol. 2013;139:755‐763.
Deek MP, Van der Eecken K, Phillips R, et al. The mutational landscape of metastatic castration‐sensitive prostate cancer: the spectrum theory revisited. Eur Urol. 2021;80:632‐640.
Deek MP, Van der Eecken K, Sutera P, et al. Long‐term outcomes and genetic predictors of response to metastasis‐directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40:3377‐3382.
Del Ben F, Turetta M, Celetti G, et al. A method for detecting circulating tumor cells based on the measurement of single‐cell metabolism in droplet‐based microfluidics. Angew Chem Int Ed. 2016;55:8581‐8584.
Brisotto G, Biscontin E, Rossi E, et al. Dysmetabolic circulating tumor cells are prognostic in metastatic breast cancer. Cancers. 2020;12:1005.
Rivello F, Matuła K, Piruska A, Smits M, Mehra N, Huck WTS. Probing single‐cell metabolism reveals prognostic value of highly metabolically active circulating stromal cells in prostate cancer. Sci Adv. 2020;6:eaaz3849.
McKinney W. Data Structures for Statistical Computing in Python. SciPy. 2010;445:51-56.
Harris CR, Millman KJ, van der Walt SJ, et al. Array programming with NumPy. Nature. 2020;585:357‐362.
Virtanen P, Gommers R, Oliphant TE, et al. SciPy 1.0: fundamental algorithms for scientific computing in python. Nat Methods. 2020;17:261‐272.
Hunter JD. Matplotlib: A 2D graphics environment. Comput Sci Eng. 2007;9:90‐95.
Waskom M. Seaborn: statistical data visualization. J Open Source Softw. 2021;6:3021.
Davidson‐Pilon C. Lifelines: survival analysis in python. J. Open Source Softw. 2019;4:1317.
Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a european society for radiotherapy and oncology and european organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21:e18‐e28.
Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449‐458.
Marvaso G, Volpe S, Pepa M, et al. Oligorecurrent prostate cancer and stereotactic body radiotherapy: where are we now? A systematic review and meta‐analysis of prospective studies. Eur Urol Open Sci. 2021;27:19‐28.
Siva S, Bressel M, Murphy DG, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74:455‐462.
Zhang H, Orme JJ, Abraha F, et al. Phase II evaluation of stereotactic ablative radiotherapy (SABR) and immunity in 11C‐Choline‐PET/CT‐Identified oligometastatic Castration‐Resistant prostate cancer. Clin Cancer Res. 2021;27:6376‐6383.
Kneebone A, Hruby G, Ainsworth H, et al. Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate‐specific membrane antigen positron emission tomography. Eur Urol Oncol. 2018;1:531‐537.
Patel PH, Chaw CL, Tree AC, Sharabiani M, van As NJ. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer. World J Urol. 2019;37:2615‐2621.
Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR. Stereotactic body radiation therapy for oligometastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2016;95:696‐702.
Palacios‐Eito A, Béjar‐Luque A, Rodríguez‐Liñán M, García‐Cabezas S. Oligometastases in prostate cancer: ablative treatment. World J Clin Oncol. 2019;10:38‐51.
Mandel PC, Huland H, Tiebel A, et al. Enumeration and changes in circulating tumor cells and their prognostic value in patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer‐translational research results from the prospective ProMPT trial. Eur Urol Focus. 2021;7:55‐62.
Goldkorn A, Tangen C, Plets M, et al. Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate sensitive prostate cancer (SWOG S1216). Clin Cancer Res. 2021;27:1967‐1973.
Yang G, Xie J, Zhang S, et al. Clinical significance of mesenchymal circulating tumor cells in patients with oligometastatic hormone‐sensitive prostate cancer who underwent cytoreductive radical prostatectomy. Front Oncol. 2022;11:812549.
Budna‐Tukan J, Świerczewska M, Mazel M, et al. Analysis of circulating tumor cells in patients with non‐metastatic high‐risk prostate cancer before and after radiotherapy using three different enumeration assays. Cancers. 2019;11:802.
Martin OA, Anderson RL, Russell PA, et al. Mobilization of viable tumor cells into the circulation during radiation therapy. Int J Radiat Oncol Biol Phys. 2014;88:395‐403.
Zapatero A, Gómez‐Caamaño A, Cabeza Rodriguez MÁ, et al. Detection and dynamics of circulating tumor cells in patients with high‐risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study. Radiat Oncol. 2020;15:137.
Klusa D, Lohaus F, Franken A, et al. Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy. Int J Cancer. 2023;152:2639‐2654.
Cieślikowski WA, Antczak A, Nowicki M, Zabel M, Budna‐Tukan J. Clinical relevance of circulating tumor cells in prostate cancer management. Biomedicines. 2021;9:1179.
Gandaglia G, Karakiewicz PI, Briganti A, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68:325‐334.
Francini E, Gray KP, Xie W, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018;78:889‐895.
Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis‐free survival in men with nonmetastatic castration‐resistant prostate cancer: exploratory analyses by baseline prostate‐specific antigen doubling time. J Clin Oncol. 2013;31:3800‐3806.
D'Angelillo RM, Francolini G, Ingrosso G, et al. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: a position paper of Italian association of radiotherapy and clinical oncology (AIRO). Crit Rev Oncol Hematol. 2019;138:24‐28.
Colosini A, Bernardi S, Foroni C, et al. Stratification of oligometastatic prostate cancer patients by liquid biopsy: clinical insights from a pilot study. Biomedicines. 2022;10:1321.